Table 3 Mean of plasma SM levels according to cardiovascular risk factors.
From: Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease
| Â | Controls | Patients | ||||
|---|---|---|---|---|---|---|
| Â | n | SM in mg/dl | p-value | n | SM in mg/dl | p-value |
Sex | Â | Â | Â | Â | Â | Â |
   female | 121 | 44.7 ± 1.2 | 0.398 | 279 | 51.3 ± 1.25 | 0.210 |
   male | 323 | 43.9 ± 1.21 |  | 823 | 50.3 ± 1.24 |  |
Diabetes mell. | Â | Â | Â | Â | Â | Â |
   - | 428 | 43.9 ± 1.21 | <0.001 | 863 | 50.7 ± 1.24 | 0.362 |
   + | 16 | 52.8 ± 1.26 |  | 239 | 49.9 ± 1.26 |  |
Hypertension | Â | Â | Â | Â | Â | Â |
   - | 317 | 44.0 ± 2.29 | 0.628 | 309 | 51.5 ± 1.25 | 0.077 |
   + | 127 | 44.4 ± 1.24 |  | 793 | 50.2 ± 1.25 |  |
Smoking | Â | Â | Â | Â | Â | Â |
   - | 395 | 43.9 ± 1.21 | 0.048 | 801 | 50.2 ± 1.24 | 0.057 |
   + | 49 | 46.4 ± 1.21 |  | 301 | 51.6 ± 1.26 |  |
Statins | Â | Â | Â | Â | Â | Â |
   - | 411 | 44.0 ± 1.21 | 0.46 | 690 | 51.0 ± 1.24 | 0.068 |
   + | 28 | 45.3 ± 1.19 |  | 395 | 49.7 ± 1.26 |  |
ACE inhibitors | Â | Â | Â | Â | Â | Â |
   - | 407 | 44.3 ± 1.21 | 0.309 | 575 | 51.3 ± 1.26 | 0.015 |
   + | 37 | 42.8 ± 1.26 |  | 527 | 49.7 ± 1.23 |  |
Ejection fraction | Â | Â | Â | Â | Â | Â |
   <40% | - | - | - | 69 | 50.4 ± 1.24 | 0.325 |
   >40% | - | - |  | 844 | 51.4 ± 1.21 |  |